Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
No large studies have defined the best treatment of actinic cheilitis.
We conducted a systematic review to define the best therapies for actinic cheilitis in clinical response and recurrences.
We first identified 444 papers, and 49 were finally considered, including 789 patients and 843 treated areas. The following therapies were recorded in order of frequency: laser therapy, photodynamic therapy (PDT), 3% diclofenac in 2.5% hyaluronic acid, PDT + 5% imiquimod, aminolevulinic acid–laser or methyl-aminolevulinic acid–laser, 5% imiquimod, fluorouracil, partial surgery, 0.015% ingenol mebutate, 50% trichloroacetic acid, and laser + PDT. Concerning the primary outcome, complete clinical response was achieved in 76.5% of patients, and 10.2% had clinical recurrences. Partial surgery and laser therapy showed the highest complete response rates (14 of 14 [100%] and 244 of 260 [93.8%], respectively) with low recurrences. Only a limited number of patients were treated with other therapies, with the exception of PDT, with 68.9% complete responses and 12.6% of recurrences. Interestingly, when combined with 5% imiquimod, the efficacy of PDT was significantly enhanced.
Heterogeneity across studies.
Laser therapy appears the best option among nonsurgical approaches for actinic cheilitis, and PDT showed higher efficacy when sequentially combined with 5% imiquimod. Larger studies are needed to confirm these data.Le texte complet de cet article est disponible en PDF.
Key words : actinic cheilitis, diclofenac, imiquimod, laser, photodynamic therapy, treatment
Abbreviations used : AC, AE, ALA, DHA, Er:YAG, FU, IMI, IngMeb, MAL, PDT, SCC, TCA
| Drs Lai and Pampena contributed equally to this work.
| Funding sources: None.
| Conflicts of interest: None.